Project description DEENESFRITPL An innovative platform revolutionises the treatment of depression Depression is one of the most significant types of mental disorders and causes of disability worldwide. The World Health Organisation and the European Commission are constantly taking measures to ensure access to mental health services without unfair financial barriers and treatments based on both efficiency and economic equity. The EU-funded Predictix project will introduce a user-friendly platform that analyses genomic, clinical and demographic data to generate a personalised report on the efficacy of antidepressants and their side effects. Through Predictix, medical practitioners will have up-to-date and accurate information on each case to improve and customise the care each patient receives. Show the project objective Hide the project objective Objective The World Health Organization recognizes mental disorders as one of the most significant public health challenges worldwide as measured by prevalence, burden of disease and disability, and depression as the world’s leading cause of disability. In EC and WHO action plans it is clearly requested that mental health services can be accessed without unfair financial barriers and that treatments are made available on criteria of both efficiency and financial fairness. Personalised medicine is the fastest, most economic and optimized solution to the depression treatment problem. The current push for a cost effective personalised medicine based on IT solution will also help with the commercialisation of our Predictix™ platform. The platform will allow medical practitioners to have up-to-date and accurate knowledge on each case and improve the care that patient receives, with an economic revenue too. Our solution allows for better delivery of available treatments – noted as a vital factor for increasing remission. Taliaz was founded in 2012 by Dr. Dekel Taliaz and Oren Taliaz. Our mission is to set a new standard in personalized medicine improving quality of life for patients suffering from depression. Taliaz takes advantage of in-house expertise in genetics, data science and central nervous system related disease with the advancements in genetic sequencing and machine learning technologies, to develop leading personal medicine proprietary IP solutions for depression. Our future vision is to use Predictix™ also as a decision support tool for common health concerns such as ADHD and Anxiety. The SME Instrument project perfectly fits our strategy and vision by enabling a fast finalisation of the platform development and by providing us the resources necessary to demonstrate the benefits of Predictix™ through a large clinical study. Fields of science medical and health scienceshealth sciencespublic healthsocial sciencespsychologypsychotherapymedical and health sciencesclinical medicinepsychiatrysocial sciencessociologydemographymedical and health scienceshealth sciencespersonalized medicine Keywords Depression predictive analysis antidepressants artificial intelligence machine learning Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator TALIAZ LTD Net EU contribution € 2 482 016,25 Address 2 prof. yehezkel kaufmann street textile center, 15th floor 6801294 Tel-aviv Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 545 737,50